GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savient Pharmaceuticals (FRA:BY7) » Definitions » Cyclically Adjusted FCF per Share

Savient Pharmaceuticals (FRA:BY7) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2013)


View and export this data going back to . Start your Free Trial

What is Savient Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Savient Pharmaceuticals's adjusted free cash flow per share for the three months ended in Sep. 2013 was €-0.182. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Sep. 2013.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-15), Savient Pharmaceuticals's current stock price is €0.03. Savient Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2013 was €0.00. Savient Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Savient Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Savient Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savient Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Savient Pharmaceuticals Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Savient Pharmaceuticals Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Mar14
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Savient Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Savient Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savient Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savient Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Savient Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Savient Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Savient Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2013 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2013 (Change)*Current CPI (Sep. 2013)
=-0.182/98.7900*98.7900
=-0.182

Current CPI (Sep. 2013) = 98.7900.

Savient Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200312 0.041 77.758 0.052
200403 0.056 79.066 0.070
200406 0.038 80.037 0.047
200409 -0.002 80.121 -0.002
200412 0.009 80.290 0.011
200503 0.029 81.555 0.035
200506 -0.069 82.062 -0.083
200509 -0.060 83.876 -0.071
200512 0.177 83.032 0.211
200603 0.016 84.298 0.019
200606 -0.001 85.606 -0.001
200609 0.007 85.606 0.008
200612 -0.341 85.142 -0.396
200703 -0.107 86.640 -0.122
200706 -0.197 87.906 -0.221
200709 -0.144 87.964 -0.162
200712 -0.130 88.616 -0.145
200803 -0.195 90.090 -0.214
200806 -0.094 92.320 -0.101
200809 -0.306 92.307 -0.327
200812 -0.238 88.697 -0.265
200903 -0.293 89.744 -0.323
200906 -0.184 91.003 -0.200
200909 -0.140 91.120 -0.152
200912 -0.223 91.111 -0.242
201003 -0.155 91.821 -0.167
201006 -0.133 91.962 -0.143
201009 -0.127 92.162 -0.136
201012 -0.181 92.474 -0.193
201103 -0.201 94.283 -0.211
201106 -0.277 95.235 -0.287
201109 -0.392 95.727 -0.405
201112 -0.343 95.213 -0.356
201203 -0.417 96.783 -0.426
201206 -0.361 96.819 -0.368
201209 -0.277 97.633 -0.280
201212 -0.217 96.871 -0.221
201303 -0.292 98.209 -0.294
201306 -0.182 98.518 -0.183
201309 -0.182 98.790 -0.182

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Savient Pharmaceuticals  (FRA:BY7) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Savient Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Savient Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Savient Pharmaceuticals (FRA:BY7) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Savient Pharmaceuticals, Inc., was founded in 1980. It develops, manufactures and markets products through the application of genetic engineering and related biotechnologies. The Company, and its wholly-owned Subsidiaries, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. It completed a promotional launch of KRYSTEXXA in the United States during the first quarter of 2011 with its sales force commencing field promotion to health care providers on February 28, 2011. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company launched its authorized generic version of oxandrolone in December 2006 in response to the approval and launch of generic competition to Oxandrin. On January 1, 2012, KRYSTEXXA received a permanent J Code, which facilitates reimbursement to providers who treat patients suffering with RCG and who rely on Medicare and Medicaid. The manufacturing process for pegloticase, which is the drug substance of KRYSTEXXA, consists of the production through a recombinant process in which a genetically-engineered bacteria produces uricase, followed by its purification, PEGylation, further purification and formulation to produce the bulk pegloticase, which the company refers it as pegloticase drug substance. Pegloticase is aseptically filtered and filled into sterile, single dose vials to produce the KRYSTEXXA drug product. Its sales force targets rheumatologists and nephrologists with access to infusion centers and healthcare institutions, each of which treat adult patients suffering from RCG, as well as podiatrists who also treat patients with RCG. In March 2012, KRYSTEXXA was made available in the EU to healthcare professionals through a Named Patient Program. The Company sells its products to three drug wholesaler customers and various specialty distributors. Its research and development includes costs associated with the research and development of its KRYSTEXXA product prior to FDA approval and FDA-related post-marketing commitments for approved products (KRYSTEXXA post-approval). These costs mainly include pre-clinical and clinical studies and trials, personnel costs including compensation, consultants and contract research organizations, or CROs, quality control and assurance costs, regulatory costs and costs related to the development of commercial scale manufacturing capabilities for KRYSTEXXA, which also includes the costs of preparing Fujifilm to serve as its secondary source supplier of pegloticase drug substance for KRYSTEXXA in the United States. As of March 7, 2013, the company owned 14 issued U.S. patents and 154 issued foreign patents. It currently owns U.S. and several foreign registrations or applicat

Savient Pharmaceuticals (FRA:BY7) Headlines

No Headlines